The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with a once-daily application treatment regimen. In clinical studies, Naftin (naftifine HCl) Gel 2% demonstrated continuous improvement in post-treatment efficacy rates for up to four weeks after treatment regimen had ended. Naftin Gel 2% will be available to physicians nationwide in the fall of 2013.